Masimo Corp (MASI) Earnings: 2Q Revenue Meets Estimates with Strong Growth Forecast

Masimo Corp on Smartkarma

Analyst coverage of Masimo Corp on Smartkarma by Baptista Research has been insightful and positive. In the report titled “Masimo Corporation: Will The Sound United Divestiture & Financial Realignment Efforts Meet Their Ultimate Goal?”, the analyst highlights Masimo’s strategic shifts and operational restructuring following a successful first quarter of 2025. The focus on core healthcare operations post the divestiture of its consumer audio business is expected to drive future growth. The analysis presents a balanced view, discussing both opportunities and challenges for Masimo moving forward.

Another report by Baptista Research, “Masimo Corporation: The Strong Contracting”, delves into Masimo’s fourth quarter and full-year 2024 financial results. With consolidated revenues reaching $601 million in the fourth quarter, showing a 9% increase on a constant currency basis, Masimo demonstrated solid performance. Healthcare revenues grew by 9%, supported by the shipment of 65,000 technology boards and monitors. The report acknowledges the company’s accomplishments while also identifying areas for improvement, providing a bullish outlook on Masimo’s prospects.

A look at Masimo Corp Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores for Masimo Corp, the company appears to have a mixed long-term outlook. While it scores moderately in terms of growth, resilience, and momentum, its value and dividend scores are relatively lower. Masimo Corp focuses on designing and developing medical signal processing and sensor technology for noninvasive monitoring of physiological parameters, particularly in improving pulse oximetry effectiveness. This indicates that while the company shows promise in certain areas, investors may need to consider the lower value and dividend aspects when assessing its overall potential.

In summary, Masimo Corporation specializes in developing innovative technology for monitoring physiological parameters noninvasively. With moderate scores in growth, resilience, and momentum, the company demonstrates potential for future development and market stability. However, the lower scores in value and dividend factors suggest that investors should carefully weigh the company’s overall outlook before making investment decisions.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma